10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2023

or

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from to

Commission File Number 001-32982

Atrion Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware	63-0821819
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

One Allentown Parkway, Allen, Texas  75002

(Address of Principal Executive Offices)   (Zip Code)

(972) 390-9800

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, Par Value $0.10 per share	ATRI	The Nasdaq Global Select  Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes  ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Registration S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   ☒ Yes    ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes   ☒ No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Title of Each Class	Number of Shares Outstanding at October 27, 2023
Common stock, Par Value $0.10 per share	1,759,836

ATRION CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS

PART I.	Financial Information		3
Item 1.	Financial Statements		4
		Condensed Consolidated Statements of Income (Unaudited) For the Three and Nine Months Ended September 30, 2023 and September 30, 2022	4
		Condensed Consolidated Balance Sheets (Unaudited) September 30, 2023 and December 31, 2022	5
		Condensed Consolidated Statements of Cash Flows (Unaudited) For the Nine Months Ended September 30, 2023 and September 30, 2022	6
		Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) For the Three and Nine Months Ended September 30, 2023 and September 30, 2022	7
		Notes to Condensed Consolidated Financial Statements (Unaudited)	9
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		20
Item 4.	Controls and Procedures		20
PART II.	Other Information		21
Item 1.	Legal Proceedings		21
Item 1A.	Risk Factors		21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		21
Item 6.	Exhibits		22
SIGNATURES			23

2

PART I

FINANCIAL INFORMATION

3

Item 1. Financial Statements.

ATRION CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
	(in thousands, except per share amounts)						(in thousands, except per share amounts)
Revenues	$	41,911		$	44,631		$	125,742		$	140,651
Cost of goods sold		28,175			26,978			79,671			82,921
Gross profit		13,736			17,653			46,071			57,730
Operating expenses:
Selling		2,348			2,306			7,392			7,451
General and administrative		5,453			4,493			17,658			15,217
Research and development		1,869			1,251			5,106			4,180
		9,670			8,050			30,156			26,848
Operating income		4,066			9,603			15,915			30,882
Interest and dividend income		320			210			687			639
Other investment income/(losses)		(782	)		764			(1,405	)		216
Other income		-			7			39			92
Interest Expense		(97	)		-			(124	)		-
		(559	)		981			(803	)		947
Income before provision for income taxes		3,507			10,584			15,112			31,829
Provision for income taxes		(568	)		(1,745	)		(2,125	)		(5,143	)
Net income	$	2,939		$	8,839		$	12,987		$	26,686
Net income per basic share	$	1.67		$	4.95		$	7.38		$	14.89
Weighted average basic shares outstanding		1,760			1,786			1,761			1,793
Net income per diluted share	$	1.67		$	4.94		$	7.37		$	14.86
Weighted average diluted shares outstanding		1,761			1,788			1,762			1,796
Dividends per common share	$	2.20		$	2.15		$	6.50		$	6.05

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

4

ATRION CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	September 30, 2023			December 31, 2022
Assets	(in thousands)
Current assets:
Cash and cash equivalents	$	658		$	4,731
Short-term investments		3,839			21,152
Accounts receivable		23,290			23,951
Inventories		82,946			65,793
Prepaid expenses and other current assets		5,010			3,770
		115,743			119,397
Long-term investments		9,474			8,669
Property, plant and equipment		284,079			270,642
Less accumulated depreciation and amortization		157,313			146,888
		126,766			123,754
Other assets and deferred charges:
Patents and licenses		1,100			1,185
Goodwill		9,730			9,730
Other		1,996			1,977
		12,826			12,892
Total assets	$	264,809		$	264,712
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	13,915		$	18,024
Accrued income and other taxes		1,351			74
		15,266			18,098
Line of credit		4,500			-
Other non-current liabilities		4,861			7,073
Stockholders’ equity:
Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares		342			342
Additional paid-in capital		67,165			66,347
Retained earnings		379,213			377,682
Treasury shares,1,660 at September 30, 2023 and 1,659 at December 31, 2022, at cost		(206,538	)		(204,830	)
Total stockholders’ equity		240,182			239,541
Total liabilities and stockholders’ equity	$	264,809		$	264,712

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

5

ATRION CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended  September 30,
	2023			2022
	(In thousands)
Cash flows from operating activities:
Net income	$	12,987		$	26,686
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		11,090			10,339
Deferred income taxes		(1,931	)		(2,391	)
Stock-based compensation		1,319			1,523
Net change in unrealized gains and losses on investments		1,405			(289	)
Net change in accrued interest, premiums, and discounts on investments		(98	)		219
Other		-			-
		24,772			36,087
Changes in operating assets and liabilities:
Accounts receivable		661			(1,015	)
Inventories		(17,153	)		(8,846	)
Prepaid expenses		(1,450	)		(575	)
Other non-current assets		191			606
Accounts payable and accrued liabilities		1,130			(403	)
Accrued income and other taxes		1,277			2,523
Other non-current liabilities		(280	)		570
Cash flows from operating activities		9,148			28,947
Cash flows from investing activities:
Property, plant and equipment additions		(19,757	)		(25,321	)
Purchase of investments		(5,648	)		(25,544	)
Proceeds from sale of investments		172			240
Proceeds from maturities of investments		20,676			42,426
Cash flows from investing activities		(4,557	)		(8,199	)
Cash flows from financing activities:
Purchase of treasury stock		(1,667	)		(14,430	)
Shares tendered for employees’ withholding taxes on stock-based compensation		(57	)		(633	)
Dividends paid		(11,440	)		(10,824	)
Proceeds from draw on line of credit		23,628			-
Repayment of draw on line of credit		(19,128	)		-
Cash flows from financing activities		(8,664	)		(25,887	)
Net change in cash and cash equivalents		(4,073	)		(5,139	)
Cash and cash equivalents at beginning of period		4,731			32,264
Cash and cash equivalents at end of period	$	658		$	27,125
Cash paid for:
Income taxes	$	3,366		$	5,786
Non-cash financing activities: Non-cash effect of stock option exercises	$	-		$	4,008

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements

6

ATRION CORPORATION AND SUBSIDIARIES
NOTES CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

	For the Three Months Ended
	Common Stock					Treasury Stock
	Shares Outstanding			Amount		Shares			Amount			Additional Paid-in Capital		Retained Earnings			Total
Balances, July 1, 2022		1,788		$	342		1,632		$	(188,219	)	$	66,167	$	368,165		$	246,455
Net income															8,839			8,839
Stock-based compensation transactions		1					(1	)		14			77					91
Shares surrendered in stock transactions										(179	)							(179	)
Purchase of treasury stock		(9	)				9			(5,090	)							(5,090	)
Dividends															(3,841	)		(3,841	)
Balances, September 30, 2022		1,780		$	342		1,640		$	(193,474	)	$	66,244	$	373,163		$	246,275
Balances, July 1, 2023		1,760		$	342		1,660		$	(206,541	)	$	66,946	$	380,152		$	240,899
Net income															2,939			2,939
Stock-based compensation transactions										3			219					222
Shares surrendered in stock transactions																		-
Purchase of treasury stock																		-
Dividends															(3,878	)		(3,878	)
Balances, September 30, 2023		1,760		$	342		1,660		$	(206,538	)	$	67,165	$	379,213		$	240,182

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

7

ATRION CORPORATION AND SUBSIDIARIES
NOTES CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

	For the Nine Months Ended
	Common Stock					Treasury Stock
	Shares Outstanding			Amount		Shares			Amount			Additional Paid-in Capital		Retained Earnings			Total
Balances, January 1, 2022		1,801		$	342		1,619		$	(174,544	)	$	61,174	$	357,324		$	244,296
Net income															26,686			26,686
Stock-based compensation transactions		4					(4	)		(3,867	)		5,070					1,203
Shares surrendered in stock transactions		(1	)				1			(633	)							(633	)
Purchase of Treasury Stock		(24	)				24			(14,430	)							(14,430	)
Dividends															(10,847	)		(10,847	)
Balances, September 30, 2022		1,780		$	342		1,640		$	(193,474	)	$	66,244	$	373,163		$	246,275
Balances, January 1, 2023		1,761		$	342		1,659		$	(204,830	)	$	66,347	$	377,682		$	239,541
Net income															12,987			12,987
Stock-based compensation transactions		1					(1	)		16			818					834
Shares surrendered in stock transactions										(57	)							(57	)
Purchase of Treasury Stock		(2	)				2			(1,667	)							(1,667	)
Dividends															(11,456	)		(11,456	)
Balances, September 30, 2023		1,760		$	342		1,660		$	(206,538	)	$	67,165	$	379,213		$	240,182

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

8

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Basis of Presentation  

The accompanying unaudited condensed consolidated financial statements of Atrion Corporation and its subsidiaries (collectively referred to herein as “Atrion,” the “Company,” “we,” “our,” or “us”) have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, these statements include all normal and recurring adjustments necessary to present a fair statement of our consolidated results of operations, financial position, and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that can have a significant impact on our revenue, operating income, and net income, as well as on the value of certain assets and liabilities on our consolidated balance sheets. We base our assumptions, judgments, and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. We are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying value of our assets or liabilities as of November 7, 2023, the date of issuance of this Quarterly Report on Form 10-Q. However, these estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. At least quarterly, we evaluate our assumptions, judgments, and estimates, and make changes as we deem necessary.

This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 ("2022 Form 10-K").

(2)  Inventories 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by using the first-in, first-out method. The following table details the major components of inventories (in thousands):

	September 30,		December 31,
	2023		2022
Raw materials	$	37,890	$	33,329
Work in process		17,036		13,618
Finished goods		28,020		18,846
Total inventories	$	82,946	$	65,793

9

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(3) Income per share 

The following is the computation for basic and diluted income per share:

	Three Months ended September 30,				Nine Months ended September 30,
	2023		2022		2023		2022
	(in thousands, except per share amounts)
Net income	$	2,939	$	8,839	$	12,987	$	26,686
Weighted average basic shares outstanding		1,760		1,786		1,761		1,793
Add: Effect of dilutive securities		1		2		1		3
Weighted average diluted shares outstanding		1,761		1,788		1,762		1,796
Earnings per share:
Basic	$	1.67	$	4.95	$	7.38	$	14.89
Diluted	$	1.67	$	4.94	$	7.37	$	14.86

Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. Potential dilutive securities have been excluded when their inclusion would be anti-dilutive. 

(4)  Investments 

As of September 30, 2023, we held investments in bonds, money market accounts, mutual funds, and equity securities. The bonds are considered held-to-maturity and are recorded at amortized cost in the accompanying consolidated balance sheets. The money market accounts, equity securities, and mutual funds are recorded at fair value in the accompanying consolidated balance sheets. The fair values of these investments were estimated using recently executed transactions and market price quotations. We consider as current assets those investments which will mature in the next 12 months including interest receivable on the long-term bonds. The remaining investments are considered non-current assets which we intend to hold longer than 12 months.

10

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The components of the Company’s cash and cash equivalents and our short- and long-term investments are as follows (in thousands):

	September 30, 2023		December 31, 2022
Cash and cash equivalents:
Money market funds	$	656	$	2,380
Cash deposits		2		603
Commercial paper		-		1,748
Total cash and cash equivalents	$	658	$	4,731
Short-term investments:
Bonds (held-to-maturity)	$	3,748	$	8,597
Equity securities (available for sale)		91		330
Commercial paper (held-to-maturity)		-		12,227
Allowance for credit losses		-		(2	)
Total short-term investments	$	3,839	$	21,152
Long-term investments:
Equity securities (available for sale)	$	3,910	$	5,139
Bonds (held-to-maturity)		3,839		3,180
Mutual funds (available for sale)		1,725		350
Total long-term investments	$	9,474	$	8,669
Total cash, cash equivalents and short and long-term investments	$	13,971	$	34,552

We utilize a lifetime “expected credit loss” measurement objective for the recognition of credit losses for held-to-maturity securities at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. During the third quarter of 2023, our allowance for credit losses was immaterial.

11

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The following table summarizes the amortized cost of our held-to-maturity bonds at September 30, 2023 aggregated by credit quality indicator (in thousands):

Held-to-Maturity Bonds

Credit Quality Indicators	Fed Govt. Bonds/Notes		Corporate Bonds		Totals
AAA/AA/A	$	104	$	3,693	$	3,797
BBB/BB		-		3,790		3,790
TOTAL	$	104	$	7,483	$	7,587

Our investments are required to be measured for disclosure purposes at fair value on a recurring basis. Our investments are considered Level 1 or Level 2 as detailed in the table below. The fair values of these investments were estimated using recently executed transactions and market price quotations. The amortized cost and fair value of our investments, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands):

					Gross Unrealized
	Level		Cost		Gains		Losses			Fair Value
As of September 30,  2023:
Money market		1		656	$	-	$	-		$	656
Commercial paper		2		-	$	-	$	-		$	-
Bonds		2		7,587	$	4	$	(144	)	$	7,447
Mutual funds		1		1,781	$	-	$	(56	)	$	1,725
Equity investments		2		6,054	$	-	$	(2,053	)	$	4,001
As of December 31, 2022:
Money Market		1		2,380	$	-	$	-		$	2,380
Commercial paper		2		13,975	$	1	$	(9	)	$	13,967
Bonds		2		11,777	$	-	$	(353	)	$	11,424
Mutual funds		1		466	$	-	$	(116	)	$	350
Equity investments		2		6,054	$	-	$	(585	)	$	5,469

The carrying value of our investments is reviewed quarterly for changes in circumstances or the occurrence of events that suggests an investment may not be fully recoverable. The bonds represent investments in various issuers at September 30, 2023. The unrealized losses for some of these bond investments reflect changes in interest rates following their acquisition. As of September 30, 2023, we had six bond investments in a loss position for more than 12 months.

At September 30, 2023, the length of time to maturity for the bonds we held ranged from less than a month to 27 months.

12

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(5)

Patents and Licenses

Patents and license fees paid for the use of other entities’ patents are amortized over the useful life of the patent or license. The following tables provide information regarding patents and licenses (dollars in thousands):

September 30, 2023						December 31, 2022
Weighted Average Original Life (years)		Gross Carrying Amount		Accumulated Amortization		Weighted Average Original Life (years)		Gross Carrying Amount		Accumulated Amortization
	15.67	$	13,840	$	12,740		15.67	$	13,840	$	12,655

Aggregated amortization expense for patents and licenses was $28 thousand in the three-month period ended September 30, 2023 and $29 thousand in the three month period ended September 30, 2022. Aggregated amortization expense for patents and licenses was $85 thousand in the nine-month period ended September 30, 2023 and $89 thousand in the nine-month period ended September 30, 2022.

Estimated future amortization expense for each of the years set forth below ending December 31 is as follows (in thousands):

2024	$	113
2025	$	112
2026	$	112
2027	$	108
2028	$	108

(6)  Revenues  

We recognize revenue when performance obligations under the terms of a contract with our customer are satisfied. This occurs with the transfer of control of our products to customers when products are shipped. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Sales and other taxes we may collect concurrent with revenue-producing activities are excluded from revenue.

A summary of revenue by geographic area, based on shipping destination, for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
United States	$	26,146	$	27,779	$	78,594	$	84,121
European Union		6,695		6,371		21,361		23,851
All other regions		9,070		10,481		25,787		32,679
Total	$	41,911	$	44,631	$	125,742	$	140,651

13

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

A summary of revenue by product line for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Fluid Delivery	$	17,717	$	19,303	$	52,591	$	64,973
Cardiovascular		17,170		16,780		51,568		50,165
Ophthalmology		2,700		1,607		6,849		4,495
Other		4,324		6,941		14,734		21,018
Total	$	41,911	$	44,631	$	125,742	$	140,651

More than 98 percent of our total revenue in the periods presented herein is pursuant to shipments initiated by a purchase order (our “contract”) and recognized at a single point in time when the performance obligation of the product being shipped is satisfied, rather than recognized over time, and is presented as a receivable on the balance sheet. Payment is typically due within 30 days.

We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments. We calculate our credit loss allowance for our trade receivables following a lifetime “expected credit loss” measurement objective. An account is written off when we determine the receivable will not be collected. Historically, bad debt has been immaterial.

We have elected to recognize the cost of shipping as an expense in cost of sales when control over the product has transferred to the customer.

We do not make any material accruals for product returns and warranty obligations because our returns and warranty obligations have been very low due to our focus on quality control.

We do not disclose the value of unsatisfied performance obligations for contracts for which we recognize revenue at the amount for which we have the right to invoice. We believe that the complexity added to our disclosures by the inclusion of a large amount of insignificant detail in attempting to disclose information about immaterial contracts would potentially obscure more useful and important information.

(7)  Recent Accounting Pronouncements 

From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board or other standards-setting bodies. We generally adopt these standards as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

We develop and manufacture products primarily for medical applications. We market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics, and other treatment centers. Our medical products primarily serve the fluid delivery, cardiovascular, and ophthalmology markets. Our other medical and non-medical products include instrumentation and disposables used in valves and inflation devices used in marine and aviation safety products.

Our products are used in a wide variety of applications by numerous customers. We encounter competition in all of our markets and compete primarily on the basis of product quality, price, engineering, customer service, and delivery time.

Our business strategy is to provide hospitals, physicians, and other healthcare providers with the tools they need to improve the lives of the patients they serve. To do so, we provide a broad selection of products in the areas of our expertise. We have diverse product lines serving primarily the fluid delivery, cardiovascular, and ophthalmic markets, and this diversity has served us well as we encounter changing market conditions. Research and development, or R&D, efforts are focused on improving current products and developing highly-engineered products that meet customer needs and serve niche markets with meaningful sales potential. Proposed new products may be subject to regulatory clearance or approval prior to commercialization and the time period for introducing a new product to the marketplace can be unpredictable. We also focus on controlling costs by investing in modern manufacturing technologies and controlling purchasing processes. We have been successful in consistently generating cash from operations and have used that cash to reduce or eliminate indebtedness, to fund capital expenditures, to make investments, to repurchase stock, and to pay dividends.

Our strategic objective is to further enhance our position in our served markets by:

· Focusing on customer needs;

· Expanding existing product lines and developing new ones;

· Investing in our future growth, while balancing the need to sensibly control cost; and

· Preserving and fostering a collaborative, entrepreneurial management culture.

For the three months ended September 30, 2023, we reported revenues of $41.9 million, down 6 percent, operating income of $4.1 million, down 58 percent, and net income of $2.9 million, down 67 percent from the three months ended September 30, 2022.

Results for the three months ended September 30, 2023

Consolidated net income totaled $2.9 million, or $1.67 per basic and diluted share, in the third quarter of 2023. This is compared with consolidated net income total of $8.8 million, or $4.95 per basic and $4.94 per diluted share, in the third quarter of 2022. The income per basic share computations are based on weighted average basic shares outstanding of 1,760 thousand in the 2023 period and 1,786 thousand in the 2022 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 1,761 thousand in the 2023 period and 1,788 thousand in the 2022 period.

15

Consolidated revenues of $41.9 million for the third quarter of 2023 were 6.1 percent lower than revenues of $44.6 million for the third quarter of 2022 Although revenues in each of the first three quarters of 2023 were down from the comparable quarters in 2022, the percentage of the spread has narrowed each quarter as supply chain shortages have eased. Our third quarter 2023 results were unfavorably impacted by an 8.2 percent decrease in Fluid Delivery revenue and a 37.7 percent decrease in Other product line revenue compared to the third quarter of 2022.

Revenues by product line were as follows (in thousands):

	Three Months Ended September 30,
	2023		2022
Fluid Delivery	$	17,717	$	19,303
Cardiovascular		17,170		16,780
Ophthalmology		2,700		1,607
Other		4,324		6,941
Total	$	41,911	$	44,631

Cost of goods sold of $28.2 million for the third quarter of 2023 was 4 percent higher than our cost of goods sold of $27.0 million for the third quarter of 2022, primarily due to increased manufacturing costs. Our cost of goods sold in the third quarter of 2023 was 67.2 percent of revenue compared to 60.4 percent of revenue in the third quarter of 2022.

Gross profit of $13.7 million in the third quarter of 2023 was $3.9 million or 22.2 percent lower than in the comparable 2022 period. Our gross profit percentage in the third quarter of 2023 was 32.8 percent of revenues compared with 39.6 percent of revenues in the third quarter of 2022. The decrease in gross profit percentage in the 2023 period compared to the 2022 period was related to higher manufacturing costs.

Our third quarter 2023 operating expenses of $9.7 million were $1.6 million higher than the operating expenses for the third quarter of 2022. This increase was attributable to a $959 thousand increase in general and administrative expenses driven by outside services and compensation, as well as a $618 thousand increase in R&D expenses, primarily related to outside services and supplies. Selling expenses increased $42 thousand, primarily related to outside services.

Operating income of $4.1 million in the third quarter of 2023 represented a $5.5 million, or 57.7 percent, decrease in operating income compared to third quarter 2022 operating income. This decrease was due to lower sales and the gross profit decrease discussed above. Operating income was 9.7 percent of revenues for the third quarter of 2023 and 21.5 percent of revenues for the third quarter of 2022.

16

Interest and dividend income in the third quarter of 2023 was $320 thousand compared with $210 thousand for the same period in the prior year. The increase in interest and dividend income was due to dividends received on equity investments in the third quarter of 2023.

Other investment income in the third quarter of 2023 was a $782 thousand loss compared with Other investment gain of $764 thousand in the third quarter of 2022. These amounts were attributable to unrealized gains and losses on equity investments resulting from changes in the market values of the investments in each quarter.

Income tax expense was $568 thousand for the third quarter of 2023 compared with $1.7 million for the third quarter of 2022. The effective tax rate for the third quarter of 2023 was 16.2 percent compared with 16.5 percent for the third quarter of 2022.

Results for the nine months ended September 30, 2023

Consolidated net income totaled $13.0 million, or $7.38 per basic and $7.37 per diluted share, in the first nine months of 2023. This is compared with consolidated net income of $26.7 million, or $14.89 per basic and $14.86 per diluted share, in the first nine months of 2022. The income per basic share computations are based on weighted average basic shares outstanding of 1,761 thousand in the 2023 period and 1,793 thousand in the 2022 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 1,762 thousand in the 2023 period and 1,796 thousand in the 2022 period.

Consolidated revenues of $125.7 million for the first nine months of 2023 were 10.6 percent lower than revenues of $140.7 million for the first nine months of 2022. This decrease in revenue was due to decreased sales volumes of 19.1 percent in Fluid Delivery and 29.9 percent in Other product lines compared to the first nine months of 2022.

Revenues by product line were as follows (in thousands):

	Nine Months Ended September 30,
	2023		2022
Fluid Delivery	$	52,591	$	64,973
Cardiovascular		51,568		50,165
Ophthalmology		6,849		4,495
Other		14,734		21,018
Total	$	125,742	$	140,651

Cost of goods sold of $79.7 million for the first nine months of 2023 was $3.3 million lower than in the comparable 2022 period. This decrease was due to lower sales volumes and increased manufacturing costs. Our cost of goods sold in the first nine months of 2023 was 63.4 percent of revenues compared to 59.0 percent of revenues in the first nine months of 2022.

17

Gross profit was $46.1 million in the first nine months of 2023 and $57.7 million in the first nine months of 2022. Our gross profit percentage was 36.6 percent of revenues in the first nine months in 2023 and 41.0 percent in 2022. The decrease in gross profit percentage in the 2023 period compared to the 2022 period was related to higher manufacturing costs.

Operating expenses of $30.2 million for the first nine months of 2023 were $3.3 million higher than the operating expenses for the first nine months of 2022. This increase was attributable to a $2.4 million increase in general and administrative expenses and a $925 thousand increase in R&D expenses, primarily driven by outside services and compensation. This increase was partially offset by a $59 thousand decrease in selling expenses.

Operating income of $15.9 million for the first nine months of 2023 represented a $15.0 million or 48.5 percent decrease in operating income as compared to the first nine months of 2022. Operating income was 12.7 percent of revenues for the first nine months of 2023 and 22.0 percent of revenues for the first nine months of 2022.

Interest and dividend income for the first nine months of 2023 was $687 thousand, compared with $639 thousand for the same period in the prior year. The increase in interest and dividend income was primarily related to an increase in dividends received on equity investments in the current-year period.

Other investment income for the first nine months of 2023 was a $1.4 million loss compared to a $216 thousand gain in the first nine months of 2022. These amounts were attributable to unrealized gains and losses on equity investments resulting from changes in the market values of our investments in each time period.

Income tax expense was $2.1 million for the first nine months in 2023 and $5.1 million for the first nine months in 2022. The effective tax rate for the first nine months of 2023 was 14.1 percent, compared with 16.2 percent for the first nine months of 2022. The decrease in the 2023 period effective tax rate was primarily related to the impact of the R&D tax credit on lower income before income taxes.

Liquidity and Capital Resources

As of September 30, 2023, we had a $75.0 million revolving credit facility with a money center bank pursuant to which the lender is obligated to make advances until February 28, 2024. The credit facility is secured by substantially all of our inventories, equipment, and accounts receivable. Interest under the credit facility is assessed at 30-day, 60-day, or 90-day Adjusted Term SOFR, as selected by us, plus 1.0 percent, and is payable monthly. We had outstanding borrowings under the credit facility at September 30, 2023 of $4.5 million, and we were in compliance with all financial covenants.

At September 30, 2023, we had a total of $14.0 million in cash and cash equivalents, short-term investments, and long-term investments. At December 31, 2022, cash and cash equivalents, short-term investments, and long-term investments totaled $34.6 million.

18

Cash flows from operating activities of $9.1 million for the nine months ended September 30, 2023 were primarily comprised of net income plus the net effect of non-cash expenses and an increase in inventory and prepaid expenses. During the first nine months of 2023, we used $19.8 million for the addition of property and equipment, $11.4 million for dividends, and $5.6 million for the purchase of investments. During the same period, our maturities and sales of investments generated $20.8 million in cash, and our cash borrowings under our credit facility at September 30, 2023 were $4.5 million. For the nine months ended September 30, 2022, cash flows from operating activities of $28.9 million were primarily comprised of net income plus the net effect of non-cash expenses and an increase in inventory. During the first nine months of 2022, we used $25.5 million for the purchase of investments, $25.3 million for the addition of property and equipment, $10.8 million for dividends, and $14.4 million for the purchase of treasury stock. During the same period, maturities and sales of investments generated $42.7 million in cash.

At September 30, 2023, we had working capital of $100.5 million, including $658 thousand in cash and cash equivalents and $3.8 million in short-term investments, compared to working capital of $101.3 million at December 31, 2022. The $822 thousand decrease in working capital during the first nine months of 2023 was primarily related to a decrease in cash and short-term investments, partially offset by an increase in inventory and prepaid expenses.

We believe that our $14.0 million in cash, cash equivalents, short-term investments, and long-term investments, along with cash flows from operations and available borrowings of up to $70.5 million under our credit facility, will be sufficient to fund our cash requirements for at least the foreseeable future. We believe that our strong financial position would allow us to access equity or debt financing should that be necessary.

COVID-19 Impact

We believe the impact of COVID-19 on our business has largely diminished at this time; however, uncertainties continue, particularly around disruptions to the global economy, supply chains, and healthcare systems. Even with the public health actions that have been taken to date, the disease may pose future risks with the emergence of new variants. We will continue to monitor COVID-19 as well as resulting legislative and regulatory changes to manage our response and assess and seek to mitigate potential adverse impacts on our business. For additional discussion regarding COVID-19 and our related risks, see Part I, Item 1A, “Risk Factors” included in our 2022 Form 10-K.

19

Forward-Looking Statements

Statements in this Management’s Discussion and Analysis and elsewhere in this Quarterly Report on Form 10-Q that are forward-looking are based upon current expectations, and actual results or future events may differ materially. Therefore, the inclusion of such forward-looking information should not be regarded as a representation by us that our objectives or plans will be achieved. Such statements include, but are not limited to, our ability to fund our cash requirements for the foreseeable future with our current assets, long-term investments, cash flow, and borrowings under our credit facility, and our access to equity and debt financing. Words such as “expects,” “believes,” “anticipates,” “intends,” “should,” “plans,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that COVID-19 leads to further material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to COVID-19; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that COVID-19 further disrupts local economies and causes economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The forward-looking statements in this Quarterly Report on Form 10-Q are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

For the quarter ended September 30, 2023, we did not experience any material changes in market risk exposures that affect the quantitative and qualitative disclosures presented in our 2022 Form 10-K.

Item 4. Controls and Procedures.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2023. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting for the quarter ended September 30, 2023 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

20

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We have no pending legal proceedings of the type described in Item 103 of Regulation S-K.

Item 1A. Risk Factors.

As of the date of this Report, there has been no material change in the risk factors described in our 2022 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuer Purchases of Equity Securities

On May 21, 2015, our Board of Directors approved a stock repurchase program pursuant to which we can repurchase up to 250,000 shares of our common stock from time to time in open market or privately-negotiated transactions. Our stock repurchase program has no expiration date but may be terminated by our Board of Directors at any time. No repurchases of our stock were made during the three months ended September 30, 2023. As of September 30, 2023, we had repurchased 121,247 shares of our common stock authorized under the program and the number of shares still available for repurchase under the program was 128,753.

21

Item 6. Exhibits.

Exhibit Index

Exhibit Number	Description
31.1	Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer
31.2	Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
32.1	Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
32.2	Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

22

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Atrion Corporation (Registrant)
Date:  November 7, 2023	By:	/s/ David A. Battat
		David A. Battat
		President and
		Chief Executive Officer
Date: November 7, 2023	By:	/s/ Cindy Ferguson
		Cindy Ferguson
		Vice President and
		Chief Financial Officer
		(Principal Accounting and   Financial Officer)

23

EX-31.1

EXHIBIT 31.1

Chief Executive Officer Certification

I, David A. Battat, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Atrion Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and we have:

 

a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and
c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)	Disclosed in this report any change in the registrant’s internal control over the financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 7, 2023	/s/ David A. Battat
	David A. Battat
	President and
	Chief Executive Officer

EX-31.2

EXHIBIT 31.2

Chief Financial Officer Certification

I, Cindy Ferguson, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Atrion Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and we have:

 

a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and
c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)	Disclosed in this report any change in the registrant’s internal control over the financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 7, 2023	/s/ Cindy Ferguson
	Cindy Ferguson
	Vice President and
	Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned officer of Atrion Corporation (the “Company”), hereby certifies, to such officer’s knowledge, that the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 7, 2023	/s/ David A. Battat
	David A. Battat
	President and Chief Executive Officer

The foregoing certification is made solely for purpose of 18 U.S.C. § 1350 and not for any other purpose.

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned officer of Atrion Corporation (the “Company”), hereby certifies, to such officer’s knowledge, that the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 7, 2023	/s/ Cindy Ferguson
	Cindy Ferguson
	Vice President and
	Chief Financial Officer

The foregoing certification is made solely for purpose of 18 U.S.C. § 1350 and not for any other purpose.

XML

Cover - shares	9 Months Ended
	Sep. 30, 2023	Oct. 27, 2023
Cover [Abstract]
Entity Registrant Name	Atrion Corporation
Entity Central Index Key	0000701288
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	false
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2023
Entity Filer Category	Large Accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		1,759,836
Entity File Number	001-32982
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	63-0821819
Entity Address Address Line 1	One Allentown Parkway
Entity Address City Or Town	Allen
Entity Address State Or Province	TX
Entity Address Postal Zip Code	75002
City Area Code	972
Local Phone Number	390-9800
Security 12b Title	Common stock, Par Value $0.10 per share
Trading Symbol	ATRI
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
Revenues	$ 41,911	$ 44,631	$ 125,742	$ 140,651
Cost of goods sold	28,175	26,978	79,671	82,921
Gross profit	13,736	17,653	46,071	57,730
Operating expenses:
Selling	2,348	2,306	7,392	7,451
General and administrative	5,453	4,493	17,658	15,217
Research and development	1,869	1,251	5,106	4,180
Total operating expense	9,670	8,050	30,156	26,848
Operating income	4,066	9,603	15,915	30,882
Interest and dividend income	320	210	687	639
Other investment income/(losses)	(782)	764	(1,405)	216
Other income	0	7	39	92
Interest Expense	(97)	0	(124)	0
Total other income expense	(559)	981	(803)	947
Income before provision for income taxes	3,507	10,584	15,112	31,829
Provision for income taxes	(568)	(1,745)	(2,125)	(5,143)
Net income	$ 2,939	$ 8,839	$ 12,987	$ 26,686
Net income per basic share	$ 1.67	$ 4.95	$ 7.38	$ 14.89
Weighted average basic shares outstanding	1,760	1,786	1,761	1,793
Net income per diluted share	$ 1.67	$ 4.94	$ 7.37	$ 14.86
Weighted average diluted shares outstanding	1,761	1,788	1,762	1,796
Dividends per common share	$ 2.20	$ 2.15	$ 6.50	$ 6.05

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 658	$ 4,731
Short-term investments	3,839	21,152
Accounts receivable	23,290	23,951
Inventories	82,946	65,793
Prepaid expenses and other current assets	5,010	3,770
Total current assets	115,743	119,397
Long-term investments	9,474	8,669
Property, plant and equipment	284,079	270,642
Less accumulated depreciation and amortization	157,313	146,888
Property plant and equipment net	126,766	123,754
Other assets and deferred charges:
Patents and licenses	1,100	1,185
Goodwill	9,730	9,730
Other	1,996	1,977
Total other assets and deferred charges	12,826	12,892
Total assets	264,809	264,712
Current liabilities:
Accounts payable and accrued liabilities	13,915	18,024
Accrued income and other taxes	1,351	74
Total current liabilities	15,266	18,098
Line of credit	4,500	0
Other non-current liabilities	4,861	7,073
Stockholders' equity:
Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares	342	342
Additional paid-in capital	67,165	66,347
Retained earnings	379,213	377,682
Treasury shares,1,660 at September 30, 2023 and 1,659 at December 31, 2022, at cost	(206,538)	(204,830)
Total stockholders' equity	240,182	239,541
Total liabilities and stockholders' equity	$ 264,809	$ 264,712

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, shares par value	$ 0.10	$ 0.10
Common stock, shares authorized	10,000	10,000
Common stock, shares issued	3,420	3,420
Treasury stock, shares	1,660	1,659

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net income	$ 12,987	$ 26,686
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,090	10,339
Deferred income taxes	(1,931)	(2,391)
Stock-based compensation	1,319	1,523
Net change in unrealized gains and losses on investments	1,405	(289)
Net change in accrued interest, premiums, and discounts on investments	(98)	219
Other	0	0
Adjustments to reconcile net income loss to cash provided by used in operating activities	24,772	36,087
Changes in operating assets and liabilities:
Accounts receivable	661	(1,015)
Inventories	(17,153)	(8,846)
Prepaid expenses	(1,450)	(575)
Other non-current assets	191	606
Accounts payable and accrued liabilities	1,130	(403)
Accrued income and other taxes	1,277	2,523
Other non-current liabilities	(280)	570
Cash flows from operating activities	9,148	28,947
Cash flows from investing activities:
Property, plant and equipment additions	(19,757)	(25,321)
Purchase of investments	(5,648)	(25,544)
Proceeds from sale of investments	172	240
Proceeds from maturities of investments	20,676	42,426
Cash flows from investing activities	(4,557)	(8,199)
Cash flows from financing activities:
Purchase of treasury stock	(1,667)	(14,430)
Shares tendered for employees' withholding taxes on stock-based compensation	(57)	(633)
Dividends paid	(11,440)	(10,824)
Proceeds from draw on line of credit	23,628	0
Repayment of draw on line of credit	(19,128)	0
Cash flows from financing activities	(8,664)	(25,887)
Net change in cash and cash equivalents	(4,073)	(5,139)
Cash and cash equivalents at beginning of period	4,731	32,264
Cash and cash equivalents at end of period	658	27,125
Cash paid for:
Income taxes	3,366	5,786
Non-cash financing activities: Non-cash effect of stock option exercises	$ 0	$ 4,008

XML

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2021		1,801	1,619
Balance, amount at Dec. 31, 2021	$ 244,296	$ 342	$ (174,544)	$ 61,174	$ 357,324
Net income	26,686				26,686
Stock-based compensation transactions, shares		4	(4)
Stock-based compensation transactions, amount	1,203		$ (3,867)	5,070
Shares surrendered in stock transactions, shares		(1)	1
Shares surrendered in stock transactions, amount	(633)		$ (633)
Purchase of Treasury Stock, shares		(24)	24
Purchase of Treasury Stock, amount	(14,430)		$ (14,430)
Dividends	(10,847)				(10,847)
Balance, shares at Sep. 30, 2022		1,780	1,640
Balance, amount at Sep. 30, 2022	246,275	$ 342	$ (193,474)	66,244	373,163
Balance, shares at Jun. 30, 2022		1,788	1,632
Balance, amount at Jun. 30, 2022	246,455	$ 342	$ (188,219)	66,167	368,165
Net income	8,839				8,839
Stock-based compensation transactions, shares		1	(1)
Stock-based compensation transactions, amount	91		$ 14	77
Purchase of Treasury Stock, shares		(9)	9
Purchase of Treasury Stock, amount	(5,090)		$ (5,090)
Dividends	(3,841)				(3,841)
Shares surrendered in stock transactions	(179)		$ (179)
Balance, shares at Sep. 30, 2022		1,780	1,640
Balance, amount at Sep. 30, 2022	246,275	$ 342	$ (193,474)	66,244	373,163
Balance, shares at Dec. 31, 2022		1,761	1,659
Balance, amount at Dec. 31, 2022	239,541	$ 342	$ (204,830)	66,347	377,682
Net income	12,987				12,987
Stock-based compensation transactions, shares		1	(1)
Stock-based compensation transactions, amount	834		$ 16	818
Purchase of Treasury Stock, shares		(2)	2
Purchase of Treasury Stock, amount	(1,667)		$ (1,667)
Dividends	(11,456)				(11,456)
Shares surrendered in stock transactions	(57)		$ (57)
Balance, shares at Sep. 30, 2023		1,760	1,660
Balance, amount at Sep. 30, 2023	240,182	$ 342	$ (206,538)	67,165	379,213
Balance, shares at Jun. 30, 2023		1,760	1,660
Balance, amount at Jun. 30, 2023	240,899	$ 342	$ (206,541)	66,946	380,152
Net income	2,939				2,939
Dividends	(3,878)				(3,878)
Shares surrendered in stock transactions	0
Stock-based compensation transactions	222		$ 3	219
Purchase of treasury stock	0
Balance, shares at Sep. 30, 2023		1,760	1,660
Balance, amount at Sep. 30, 2023	$ 240,182	$ 342	$ (206,538)	$ 67,165	$ 379,213

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2023

Basis of Presentation

Basis Of Presentation

(1) Basis of Presentation  

The accompanying unaudited condensed consolidated financial statements of Atrion Corporation and its subsidiaries (collectively referred to herein as “Atrion,” the “Company,” “we,” “our,” or “us”) have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, these statements include all normal and recurring adjustments necessary to present a fair statement of our consolidated results of operations, financial position, and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that can have a significant impact on our revenue, operating income, and net income, as well as on the value of certain assets and liabilities on our consolidated balance sheets. We base our assumptions, judgments, and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. We are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying value of our assets or liabilities as of November 7, 2023, the date of issuance of this Quarterly Report on Form 10-Q. However, these estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. At least quarterly, we evaluate our assumptions, judgments, and estimates, and make changes as we deem necessary.

This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 ("2022 Form 10-K").

XML

Inventories

9 Months Ended

Sep. 30, 2023

Inventories

Inventories

(2)  Inventories 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by using the first-in, first-out method. The following table details the major components of inventories (in thousands):

	September 30,		December 31,
	2023		2022
Raw materials	$	37,890	$	33,329
Work in process		17,036		13,618
Finished goods		28,020		18,846
Total inventories	$	82,946	$	65,793

XML

Income Per Share

9 Months Ended

Sep. 30, 2023

Income Per Share

Income Per Share

(3) Income per share 

The following is the computation for basic and diluted income per share:

	Three Months ended September 30,				Nine Months ended September 30,
	2023		2022		2023		2022
	(in thousands, except per share amounts)
Net income	$	2,939	$	8,839	$	12,987	$	26,686
Weighted average basic shares outstanding		1,760		1,786		1,761		1,793
Add: Effect of dilutive securities		1		2		1		3
Weighted average diluted shares outstanding		1,761		1,788		1,762		1,796
Earnings per share:
Basic	$	1.67	$	4.95	$	7.38	$	14.89
Diluted	$	1.67	$	4.94	$	7.37	$	14.86

Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. Potential dilutive securities have been excluded when their inclusion would be anti-dilutive. 

XML

Investments

9 Months Ended

Sep. 30, 2023

Investments

Investments

(4)  Investments 

As of September 30, 2023, we held investments in bonds, money market accounts, mutual funds, and equity securities. The bonds are considered held-to-maturity and are recorded at amortized cost in the accompanying consolidated balance sheets. The money market accounts, equity securities, and mutual funds are recorded at fair value in the accompanying consolidated balance sheets. The fair values of these investments were estimated using recently executed transactions and market price quotations. We consider as current assets those investments which will mature in the next 12 months including interest receivable on the long-term bonds. The remaining investments are considered non-current assets which we intend to hold longer than 12 months.

The components of the Company’s cash and cash equivalents and our short- and long-term investments are as follows (in thousands):

	September 30, 2023		December 31, 2022
Cash and cash equivalents:
Money market funds	$	656	$	2,380
Cash deposits		2		603
Commercial paper		-		1,748
Total cash and cash equivalents	$	658	$	4,731
Short-term investments:
Bonds (held-to-maturity)	$	3,748	$	8,597
Equity securities (available for sale)		91		330
Commercial paper (held-to-maturity)		-		12,227
Allowance for credit losses		-		(2	)
Total short-term investments	$	3,839	$	21,152
Long-term investments:
Equity securities (available for sale)	$	3,910	$	5,139
Bonds (held-to-maturity)		3,839		3,180
Mutual funds (available for sale)		1,725		350
Total long-term investments	$	9,474	$	8,669
Total cash, cash equivalents and short and long-term investments	$	13,971	$	34,552

We utilize a lifetime “expected credit loss” measurement objective for the recognition of credit losses for held-to-maturity securities at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. During the third quarter of 2023, our allowance for credit losses was immaterial.

The following table summarizes the amortized cost of our held-to-maturity bonds at September 30, 2023 aggregated by credit quality indicator (in thousands):

Held-to-Maturity Bonds

Credit Quality Indicators	Fed Govt. Bonds/Notes		Corporate Bonds		Totals
AAA/AA/A	$	104	$	3,693	$	3,797
BBB/BB		-		3,790		3,790
TOTAL	$	104	$	7,483	$	7,587

Our investments are required to be measured for disclosure purposes at fair value on a recurring basis. Our investments are considered Level 1 or Level 2 as detailed in the table below. The fair values of these investments were estimated using recently executed transactions and market price quotations. The amortized cost and fair value of our investments, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands):

					Gross Unrealized
	Level		Cost		Gains		Losses			Fair Value
As of September 30,  2023:
Money market		1		656	$	-	$	-		$	656
Commercial paper		2		-	$	-	$	-		$	-
Bonds		2		7,587	$	4	$	(144	)	$	7,447
Mutual funds		1		1,781	$	-	$	(56	)	$	1,725
Equity investments		2		6,054	$	-	$	(2,053	)	$	4,001
As of December 31, 2022:
Money Market		1		2,380	$	-	$	-		$	2,380
Commercial paper		2		13,975	$	1	$	(9	)	$	13,967
Bonds		2		11,777	$	-	$	(353	)	$	11,424
Mutual funds		1		466	$	-	$	(116	)	$	350
Equity investments		2		6,054	$	-	$	(585	)	$	5,469

The carrying value of our investments is reviewed quarterly for changes in circumstances or the occurrence of events that suggests an investment may not be fully recoverable. The bonds represent investments in various issuers at September 30, 2023. The unrealized losses for some of these bond investments reflect changes in interest rates following their acquisition. As of September 30, 2023, we had six bond investments in a loss position for more than 12 months.

At September 30, 2023, the length of time to maturity for the bonds we held ranged from less than a month to 27 months.

XML

Patents and Licenses

9 Months Ended

Sep. 30, 2023

Patents and Licenses

Patents And Licenses

(5)

Patents and Licenses

Patents and license fees paid for the use of other entities’ patents are amortized over the useful life of the patent or license. The following tables provide information regarding patents and licenses (dollars in thousands):

September 30, 2023						December 31, 2022
Weighted Average Original Life (years)		Gross Carrying Amount		Accumulated Amortization		Weighted Average Original Life (years)		Gross Carrying Amount		Accumulated Amortization
	15.67	$	13,840	$	12,740		15.67	$	13,840	$	12,655

Aggregated amortization expense for patents and licenses was $28 thousand in the three-month period ended September 30, 2023 and $29 thousand in the three month period ended September 30, 2022. Aggregated amortization expense for patents and licenses was $85 thousand in the nine-month period ended September 30, 2023 and $89 thousand in the nine-month period ended September 30, 2022.

Estimated future amortization expense for each of the years set forth below ending December 31 is as follows (in thousands):

2024	$	113
2025	$	112
2026	$	112
2027	$	108
2028	$	108

XML

Revenues

9 Months Ended

Sep. 30, 2023

Revenues

Revenues

(6)  Revenues  

We recognize revenue when performance obligations under the terms of a contract with our customer are satisfied. This occurs with the transfer of control of our products to customers when products are shipped. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Sales and other taxes we may collect concurrent with revenue-producing activities are excluded from revenue.

A summary of revenue by geographic area, based on shipping destination, for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
United States	$	26,146	$	27,779	$	78,594	$	84,121
European Union		6,695		6,371		21,361		23,851
All other regions		9,070		10,481		25,787		32,679
Total	$	41,911	$	44,631	$	125,742	$	140,651

A summary of revenue by product line for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Fluid Delivery	$	17,717	$	19,303	$	52,591	$	64,973
Cardiovascular		17,170		16,780		51,568		50,165
Ophthalmology		2,700		1,607		6,849		4,495
Other		4,324		6,941		14,734		21,018
Total	$	41,911	$	44,631	$	125,742	$	140,651

More than 98 percent of our total revenue in the periods presented herein is pursuant to shipments initiated by a purchase order (our “contract”) and recognized at a single point in time when the performance obligation of the product being shipped is satisfied, rather than recognized over time, and is presented as a receivable on the balance sheet. Payment is typically due within 30 days.

We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments. We calculate our credit loss allowance for our trade receivables following a lifetime “expected credit loss” measurement objective. An account is written off when we determine the receivable will not be collected. Historically, bad debt has been immaterial.

We have elected to recognize the cost of shipping as an expense in cost of sales when control over the product has transferred to the customer.

We do not make any material accruals for product returns and warranty obligations because our returns and warranty obligations have been very low due to our focus on quality control.

We do not disclose the value of unsatisfied performance obligations for contracts for which we recognize revenue at the amount for which we have the right to invoice. We believe that the complexity added to our disclosures by the inclusion of a large amount of insignificant detail in attempting to disclose information about immaterial contracts would potentially obscure more useful and important information.

XML

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2023

Recent Accounting Pronouncements

Recent Accounting Pronouncements

(7)  Recent Accounting Pronouncements 

From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board or other standards-setting bodies. We generally adopt these standards as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2023

Inventories

Schedule Of Inventories

	September 30,		December 31,
	2023		2022
Raw materials	$	37,890	$	33,329
Work in process		17,036		13,618
Finished goods		28,020		18,846
Total inventories	$	82,946	$	65,793

XML

Income Per Share (Tables)

9 Months Ended

Sep. 30, 2023

Income Per Share

Schedule Of Computation Of Basic And Diluted Income Per Share

	Three Months ended September 30,				Nine Months ended September 30,
	2023		2022		2023		2022
	(in thousands, except per share amounts)
Net income	$	2,939	$	8,839	$	12,987	$	26,686
Weighted average basic shares outstanding		1,760		1,786		1,761		1,793
Add: Effect of dilutive securities		1		2		1		3
Weighted average diluted shares outstanding		1,761		1,788		1,762		1,796
Earnings per share:
Basic	$	1.67	$	4.95	$	7.38	$	14.89
Diluted	$	1.67	$	4.94	$	7.37	$	14.86

XML

Investments (Tables)

9 Months Ended

Sep. 30, 2023

Investments

Schedule Of Cash And Cash Equivalents Andshort And Long-term Investments

	September 30, 2023		December 31, 2022
Cash and cash equivalents:
Money market funds	$	656	$	2,380
Cash deposits		2		603
Commercial paper		-		1,748
Total cash and cash equivalents	$	658	$	4,731
Short-term investments:
Bonds (held-to-maturity)	$	3,748	$	8,597
Equity securities (available for sale)		91		330
Commercial paper (held-to-maturity)		-		12,227
Allowance for credit losses		-		(2	)
Total short-term investments	$	3,839	$	21,152
Long-term investments:
Equity securities (available for sale)	$	3,910	$	5,139
Bonds (held-to-maturity)		3,839		3,180
Mutual funds (available for sale)		1,725		350
Total long-term investments	$	9,474	$	8,669
Total cash, cash equivalents and short and long-term investments	$	13,971	$	34,552

Schedule Of Investments, Held-to-maturity Securities

Credit Quality Indicators	Fed Govt. Bonds/Notes		Corporate Bonds		Totals
AAA/AA/A	$	104	$	3,693	$	3,797
BBB/BB		-		3,790		3,790
TOTAL	$	104	$	7,483	$	7,587

Schedule Of Gross Unrealized Gains And Losses On Investments

					Gross Unrealized
	Level		Cost		Gains		Losses			Fair Value
As of September 30,  2023:
Money market		1		656	$	-	$	-		$	656
Commercial paper		2		-	$	-	$	-		$	-
Bonds		2		7,587	$	4	$	(144	)	$	7,447
Mutual funds		1		1,781	$	-	$	(56	)	$	1,725
Equity investments		2		6,054	$	-	$	(2,053	)	$	4,001
As of December 31, 2022:
Money Market		1		2,380	$	-	$	-		$	2,380
Commercial paper		2		13,975	$	1	$	(9	)	$	13,967
Bonds		2		11,777	$	-	$	(353	)	$	11,424
Mutual funds		1		466	$	-	$	(116	)	$	350
Equity investments		2		6,054	$	-	$	(585	)	$	5,469

XML

Patents and Licenses (Tables)

9 Months Ended

Sep. 30, 2023

Patents and Licenses

Schedule Of Patents And Licenses

September 30, 2023						December 31, 2022
Weighted Average Original Life (years)		Gross Carrying Amount		Accumulated Amortization		Weighted Average Original Life (years)		Gross Carrying Amount		Accumulated Amortization
	15.67	$	13,840	$	12,740		15.67	$	13,840	$	12,655

Schedule Of Estimated Future Amortization Expense

2024	$	113
2025	$	112
2026	$	112
2027	$	108
2028	$	108

XML

Revenues (Tables)

9 Months Ended

Sep. 30, 2023

Revenues

Schedule Of Revenues By Geographic Area

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
United States	$	26,146	$	27,779	$	78,594	$	84,121
European Union		6,695		6,371		21,361		23,851
All other regions		9,070		10,481		25,787		32,679
Total	$	41,911	$	44,631	$	125,742	$	140,651

Schedule Of Revenues By Product

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Fluid Delivery	$	17,717	$	19,303	$	52,591	$	64,973
Cardiovascular		17,170		16,780		51,568		50,165
Ophthalmology		2,700		1,607		6,849		4,495
Other		4,324		6,941		14,734		21,018
Total	$	41,911	$	44,631	$	125,742	$	140,651

XML

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventories
Raw material	$ 37,890	$ 33,329
Work in process	17,036	13,618
Finished goods	28,020	18,846
Total inventories	$ 82,946	$ 65,793

XML

Income per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income per share (Details)
Net income	$ 2,939	$ 8,839	$ 12,987	$ 26,686
Weighted average basic shares outstanding outstanding	1,760	1,786	1,761	1,793
Add: Effect of dilutive securities	1	2	1	3
Weighted average diluted shares outstanding	1,761	1,788	1,762	1,796
Basic	$ 1.67	$ 4.95	$ 7.38	$ 14.89
Diluted	$ 1.67	$ 4.94	$ 7.37	$ 14.86

XML

Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Cash and cash equivalents
Money market funds	$ 656	$ 2,380
Cash deposits	2	603
Commercial paper	0	1,748
Total cash and cash equivalents	658	4,731
Short-term investments
Bonds (held-to-maturity)	3,748	8,597
Equity securities (available for sale)	91	330
Commercial paper (held-to-maturity)	0	12,227
Allowance for credit losses	0	(2)
Total short-term investments	3,839	21,152
Long-term investments
Equity securities (available for sale)	3,910	5,139
Bonds (held-to-maturity)	3,839	3,180
Mutual funds (available for sale)	1,725	350
Total long-term investments	9,474	8,669
Total cash, cash equivalents and short and long-term investments	$ 13,971	$ 34,552

XML

Investments (Details 1) $ in Thousands	Sep. 30, 2023 USD ($)
Total held to Maturity Bonds	$ 7,587
AAA /AA/A [Member]
Debt Securities, Held-to-maturity	3,797
BBB/BB [Member]
Debt Securities, Held-to-maturity	3,790
Corporate Bonds [Member]
Debt Securities, Held-to-maturity	7,483
Corporate Bonds [Member] | AAA /AA/A [Member]
Debt Securities, Held-to-maturity	3,693
Corporate Bonds [Member] | BBB/BB [Member]
Debt Securities, Held-to-maturity	3,790
Fed Govt. Bonds/Notes [Member] | AAA /AA/A [Member]
Debt Securities, Held-to-maturity	104
Fed Govt. Bonds/Notes [Member] | BBB/BB [Member]
Debt Securities, Held-to-maturity	0
Fedral government bond notes [Member]
Debt Securities, Held-to-maturity	$ 104

XML

Investments (Details 2) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Money Market Funds [Member]
Debt Securities, Held-to-maturity	$ 656	$ 2,380
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Gross Unrealized Fair Value	656	2,380
Commercial Paper [Member]
Debt Securities, Held-to-maturity	0	13,975
Gross Unrealized Gains	0	1
Gross Unrealized Losses	0	(9)
Gross Unrealized Fair Value	0	13,967
Bonds [Member]
Debt Securities, Held-to-maturity	7,587	11,777
Gross Unrealized Gains	4	0
Gross Unrealized Losses	(144)	(353)
Gross Unrealized Fair Value	7,447	11,424
Mutual funds (available for sale) [Member]
Debt Securities, Held-to-maturity	1,781	466
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(56)	(116)
Gross Unrealized Fair Value	1,725	350
Equity investments [Member]
Debt Securities, Held-to-maturity	6,054	6,054
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(2,053)	(585)
Gross Unrealized Fair Value	$ 4,001	$ 5,469

XML

Investments (Details Narrative)	9 Months Ended
	Sep. 30, 2023
Investments
Securities Maturity, Description	the length of time to maturity for the bonds we held ranged from less than a month to 27 months

XML

Patents and Licenses (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Patents and Licenses
Accumulated Amortization	$ 12,740	$ 12,655
Weighted Average Original Life (years)	15 years 8 months 1 day	15 years 8 months 1 day
Gross Carrying Amount	$ 13,840	$ 13,840

XML

Patents and Licenses (Details 1) $ in Thousands	Sep. 30, 2023 USD ($)
Patents and Licenses
2024	$ 113
2025	112
2026	112
2027	108
2028	$ 108

XML

Patents and Licenses (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Patents And Licenses [Member]
Aggregate amortization expense	$ 28	$ 29	$ 85	$ 89

XML

Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 41,911	$ 44,631	$ 125,742	$ 140,651
European Union
Revenues	6,695	6,371	21,361	23,851
All Other Regions
Revenues	9,070	10,481	25,787	32,679
United State
Revenues	$ 26,146	$ 27,779	$ 78,594	$ 84,121

XML

Revenues (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 41,911	$ 44,631	$ 125,742	$ 140,651
Fluid Delivery [Member]
Revenues	17,717	19,303	52,591	64,973
Cardiovascular [Member]
Revenues	17,170	16,780	51,568	50,165
Ophthalmology [Member]
Revenues	2,700	1,607	6,849	4,495
Other [Member]
Revenues	$ 4,324	$ 6,941	$ 14,734	$ 21,018